Literature DB >> 19895904

Lipoprotein-associated phospholipase A2 decreases oxidized lipoprotein cellular association by human macrophages and hepatocytes.

Ming Yang1, Eugene M Chu, Muriel J Caslake, Celina Edelstein, Angelo M Scanu, John S Hill.   

Abstract

We investigated whether the presence of endogenous or exogenous lipoprotein-associated phospholipase A2 (Lp-PLA2) can modify the cellular association of oxidized low density lipoprotein (oxLDL) and oxidized lipoprotein(a) (oxLp(a)) by human monocyte-derived macrophages (MDM) and hepatocytes (HepG2). Purified recombinant Lp-PLA2 was used as a source of exogenous enzyme whereas Pefabloc (serine esterase inhibitor) was used to inhibit the endogenous Lp-PLA2 activity associated with isolated lipoproteins. Cellular association studies were performed with DiI-labeled oxLDL or oxLp(a) and human monocyte-derived macrophages and HepG2 cells. Active Lp-PLA2 decreased the cellular association of oxLDL and oxLp(a) in macrophages and HepG2 cells by approximately 30-40%, whereas the inactive enzyme did not significantly change oxidized lipoprotein cellular association by either cell type. OxLDL pretreated by Pefabloc increased oxLDL cellular association by MDM and HepG2 cells compared to untreated oxLDL. Therefore, unlike some lipases, Lp-PLA2 did not appear to have any catalytic independent function in oxLDL cellular association. To assess whether the reduced cellular association mediated by Lp-PLA2 was due to the hydrolysis of oxidized phosphatidylcholine (oxPC), we measured the concentration of lysophosphatidylcholine (lysoPC) in lipoprotein fractions after Lp-PLA2 treatment. LysoPC was increased by 20% (0.4 microM) and 87% (0.7 microM) by active Lp-PLA2 compared to inactive Lp-PLA2 for oxLDL and Lp(a), respectively. LysoPC at higher concentration dose-dependently increased the cellular association of oxLDL and oxLp(a) in MDM and HepG2 cells. We conclude that Lp-PLA2 mediates a decrease in oxidized lipoprotein cellular association in human macrophages and HepG2 cells by reducing the concentration of oxPC within these lipoproteins. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19895904     DOI: 10.1016/j.bbalip.2009.10.011

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages.

Authors:  Konstantinos P Markakis; Maria K Koropouli; Stavroula Grammenou-Savvoglou; Ewoud C van Winden; Andromaxi A Dimitriou; Constantinos A Demopoulos; Alexandros D Tselepis; Eleni E Kotsifaki
Journal:  J Lipid Res       Date:  2010-03-23       Impact factor: 5.922

Review 3.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

4.  Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.

Authors:  Laura Jackisch; Warunee Kumsaiyai; Jonathan D Moore; Nasser Al-Daghri; Ioannis Kyrou; Thomas M Barber; Harpal Randeva; Sudhesh Kumar; Gyanendra Tripathi; Philip G McTernan
Journal:  Diabetologia       Date:  2018-02-09       Impact factor: 10.122

5.  Effects of dl-3-n-butylphthalide on serum lipoprotein-associated phospholipase A2 and hypersensitive C-reactive protein levels in acute cerebral infarction.

Authors:  Xiao-Lei Zhang; Yin-Tao Dong; Yi Liu; Yi Zhang; Ting-Ting Li; Feng-Yun Hu
Journal:  Brain Behav       Date:  2019-11-13       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.